Current Report · Items 7.01, 9.01 · 8-K

Integra LifeSciences Holdings Corporation

IARTNASDAQEQUITYCurrent

Regulation FD Disclosure

Filed Sep 8, 2026Accepted Sep 8, 2026, 6:30 AM EDTCIK 917520Accession 0000917520-26-000061

Company context

Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver transformative care.

Current securities

IARTNASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 7.01Item 7.01 - Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. Integra LifeSciences Holdings Corporation (the “Company”) hereby furnishes the updated investor presentation attached as Exhibit 99.1 to this Current Report on Form 8-K, which the Company may use, from time to time, in presentations to existing or prospective lenders in connection with the Company’s previously-disclosed plans to refinance its outstanding senior credit facility in 2026. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liability of such section, nor shall it be deemed incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.

Get the free weekly BCS email.